Effectiveness and safety of long‐term therapy with alirocumab in acute coronary syndrome patients: A single‐centre retrospective real‐world study
There was a significant reduction in LDL-C levels with alirocumab with or without lipid-lowering therapy treatment in ACS patients in this real-world evidence study. The percentage of patients achieving LDL-C goals of <1.00 and <1.40 mmol/L were significantly higher than baseline 6 months after the adding alirocumab.
Authors
- Rufeng Huang (ORCID: https://orcid.org/0009-0000-3177-2001)
- Linghua Chen
- Mengshuang Li (ORCID: https://orcid.org/0009-0000-5213-8392)
- Zhaoqi Huang
- Ziqiu Chen (ORCID: https://orcid.org/0000-0002-3268-9282)
- Xin Yang (ORCID: https://orcid.org/0000-0002-5217-0795)
- Yecheng Deng
Institutions
- Third Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1002/bcp.70072
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00